PT-141: Research, Dosing, and Where to Buy in 2026
A research-first profile for PT-141 (Bremelanotide, Vyleesi), aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
Selective melanocortin receptor agonist (MC3R/MC4R focus). As of July 2026, The Peptide Wiki aggregates 14 PubMed-cited papers, 2 attributed expert mentions, 3 transcript dosing protocols, and 2 referenced vendors for PT-141, each linked to its source.
- Also indexed as Bremelanotide, Vyleesi.
- Selective melanocortin receptor agonist (MC3R/MC4R focus). FDA-approved as Vyleesi (Bremelanotide) for hypoactive sexual desire disorder in premenopausal women.
- Mechanism notes include MC3R/MC4R agonist in the hypothalamus, separate from peripheral tanning pathway.
- 3 aggregated dosing-protocol mentions from source transcripts.
- 14 PubMed-indexed citations listed in the research table below.
- 2 vendor recommendations captured from named experts.
- Evidence level in this entry is marked as fda_approved.
What is PT-141?
Selective melanocortin receptor agonist (MC3R/MC4R focus). FDA-approved as Vyleesi (Bremelanotide) for hypoactive sexual desire disorder in premenopausal women.
Experts on background and overview · 1 cited mention
"PT-141. that's not dopamine pathway, but it does improve libido. Like a PT-141 nasal spray with oxytocin."
How does PT-141 work?
MC3R/MC4R agonist in the hypothalamus, separate from peripheral tanning pathway.
Mechanism note
These mechanisms are presented as research observations and hypotheses from the indexed data, not as confirmation of clinical effect in humans.
What is PT-141 researched for?
Increases sexual desire and arousal. More targeted than MT2 - isolated sexual benefits without much tanning effect.
Experts on uses and effects · 1 cited mention
"PT-141 off to the other side. From what we see, PT141 is more isolated for the sexual benefits. You'll see it prescribed to women as Bremelanotide for women who are experiencing asexuality or anorgasmia."
PT-141 Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
| Speaker | Source | Timestamp | Protocol | Evidence |
|---|---|---|---|---|
| Nick | I figured out how to make RETA work 10X better | 00:17:42 | Nick reported using 1 to 2 milligrams subq on an as-needed basis, roughly 1 to 2 hours before sexual activity. He noted the sweet spot was two to three times per week throughout a cycle with as-needed layering. He found starting at the lower end helpful due to experiencing transient nausea and facial flushing, and reported effects lasting up to 72 hours. | anecdotal |
| Vigorous Steve | Staying Dry On A Cut, Injectable Oral AAS, Sleep: GH Secretagogues... | 01:24:36 | Vigorous Steve reported using a combined intranasal libido spray containing 1 mg PT-141 and 100 mcg oxytocin (anecdotal, source video zKQowBZmg7U). Research compound - not for human consumption. | anecdotal |
| Cortex Labs (Ryan Ballow) | THE 5 BEST TRT ADD-ONS Rated on a 1-10 SCALE | 00:03:50 | 0.5 to 2 mg per dose; effect duration 8 to 14 hours; onset unpredictable (1 to 13 hours). Users reported dosing sparingly on a one-off basis rather than 3+ times per week; tachyphylaxis from hypothalamic dopamine regulation has been reported in user accounts and research. | anecdotal |
Where to Buy PT-141 in 2026
APR Health Solutions
Code: NYLE (per Nyle's podcast affiliate)Visit vendor → View profile →Recommended by Nyle at 00:34:30.
APR Health Solutions
Code: NYLE (per Nyle's podcast affiliate)Visit vendor → View profile →Recommended by Promo voice at 00:24:58.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
What Experts Say
2 experts across our source library discuss PT-141. Each entry is that expert’s most context-rich mention: click to watch it at the exact timestamp in the original video. Quotes are also emitted as Schema.org Quotation JSON-LD for AI assistants.
-
“PT-141. that's not dopamine pathway, but it does improve libido. Like a PT-141 nasal spray with oxytocin.”
-
“PT-141 off to the other side. From what we see, PT141 is more isolated for the sexual benefits. You'll see it prescribed to women as Bremelanotide for women who are experiencing asexuality or anorgasmia.”
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Mechanism Research Snapshot
PT-141 research is heavily mechanism-focused: receptor targets, signaling pathways, and pharmacokinetic findings from peer-reviewed PubMed trials. Each line links to the original paper.
- "Their resistance to proteolytic degradation, enhanced conformational rigidity, and reduced immunogenicity make them especially valuable in designing long-acting and receptor-selective therapeutics." · Tran L et al, 2026 PubMed
- "Nine peptides were identified spanning diverse aging interventions: metabolic restoration (tirzepatide), telomere biology (epitalon), dermal regeneration (GHK-Cu), tissue repair (BPC-157, TB-500), neuroprotection (Semax), growth hormone modulation (CJC-1295, ipamorelin), and sexual function (bremelanotide)." · Mavrych V et al, 2026 PubMed
- "Fezolinetant is a novel neurokinin 3 receptor antagonist that has demonstrated clinical benefit in patients without a history of breast cancer." · Fuhrman J et al, 2025 PubMed
- "For libido management, flibanserin and bremelanotide act as serotonin/dopaminergic modulators and melanocortin receptor agonists, respectively." · Fuhrman J et al, 2025 PubMed
- "Among them, α-MSH analogs play a role in atopic dermatitis and scleroderma, and MC1R agonist Dersimelagon has shown effectiveness in systemic sclerosis." · Bardhan M et al, 2025 PubMed
- "The FDA has also approved various melanocortin agonists, i.e., Bremelanotide, Afamelanotide, and Setmelanotide, for the treatment of hypoactive sexual desire disorder, Erythropoietic protoporphyria, and obesity, due to pro-opiomelanocortin and leptin receptor deficiency, respectively." · Bardhan M et al, 2025 PubMed
- "Top-ranking compounds underwent further evaluation through MD simulations to assess binding stability and conformational dynamics." · Serilmez M et al, 2025 PubMed
- "In beagle dogs, the bioavailability of semaglutide (4.11 kDa) was substantially improved compared to the commercially available tablet, with an application time of only 10 min." · Krupke H et al, 2025 PubMed
- "Additionally, the patch achieved a relative bioavailability of 26% for bremelanotide (1.03 kDa) compared to subcutaneous administration." · Krupke H et al, 2025 PubMed
- "PT-141 and PnPP-19 show efficacy through central nervous system activation and nitric oxide regulation, while L-arginine and L-citrulline enhance endothelial function." · Ila V et al, 2025 PubMed
Research and Studies
14 PubMed-indexed papers reference PT-141. Top 14 shown.
Legal Status
PT-141 is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-09.
Frequently Asked Questions
What is PT-141?
Selective melanocortin receptor agonist (MC3R/MC4R focus). FDA-approved as Vyleesi (Bremelanotide) for hypoactive sexual desire disorder in premenopausal women.
Is PT-141 FDA-approved?
PT-141 is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
What dosing is reported for PT-141?
This page aggregates 3 dosing-protocol mention(s) from named-expert transcripts, each linked to a verbatim source timestamp. See the Dosing Protocols table above. Mentions are anecdotal, not medical advice.
Where can I buy PT-141?
2 vendor recommendation(s) are tracked in our directory, sourced from named-expert mentions. See the Where to Buy section above. Always verify COA and current regulatory status.
How much research has been published on PT-141?
14 PubMed-indexed paper(s) reference PT-141 in our current research feed. See the Research and Studies section above for citations.